Article Contents ::
- 1 The Brand Name ACIVIR Has Generic Salt :: Acyclovir
- 2 ACIVIR Is From Company Cipla Priced :: Rs. 321
- 3 ACIVIR have Acyclovir is comes under Sub class #N/A of Main Class #N/A
- 4 Main Medicine Class:: #N/A Sub Medicine Class :: #N/A
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name ACIVIR Has Generic Salt :: Acyclovir
ACIVIR Is From Company Cipla Priced :: Rs. 321
ACIVIR have Acyclovir is comes under Sub class #N/A of Main Class #N/A
Main Medicine Class:: #N/A Sub Medicine Class :: #N/A
Salt Name : OR Generic Name | Form | Price : MRP /Probable | Packing | ||
Acyclovir | INF | Rs. 321 | 10ML |
Brand Name | Company / Manufacturers | Strength | Unit | Price / 10ML |
ACIVIR | Cipla | 25MG/ML | 10ML | Rs. 321 |
Company Brand Name | Salt Combination | Main Medical Class | Sub Medical Class |
From Cipla :: ACIVIR | Acyclovir | #N/A | #N/A |
Indications for Drugs ::
Herpes simplex infections,Varicella zoster (chickenpox),Herpes zoster (shingles),Genital herpes
Drug Dose ::
Oral Primary herpes simplex infections Adult: 200 mg 5 times daily every 4 hr for 5-10 days; for severely immuno compromised patients and those with impaired absorption: 400 mg 5 times daily for 5 days. Suppression of recurrent herpes simplex Adult: 800 mg daily in 2-4 divided doses. May reduce to 400-600 mg daily if necessary. Reassess the condition every 6-12 mth. For mild or infrequent recurrences: Episodic treatment may be used: 200 mg 5 times daily for 5 days, preferably begun during the prodromal period. Prophylaxis of herpes simplex in immunocompromised patients Adult: 200-400 mg 4 times daily. Child: >2 yr: 200-400 mg 4 times daily; <2 yr: 100-200 mg 4 times daily. Renal impairment: CrCl (ml/min) <10: 200 mg every 12 hr. Varicella zoster Adult: >40 kg: 800 mg 4 times daily for 5 days. Child: >2 yr and <40 kg: 20 mg/kg (up to 800 mg) 4 times daily for 5 days. Herpes zoster (shingles) Adult: 800 mg 5 times daily for 7-10 days. Child: >6 yr: 800 mg 4 times daily; 2-5 yr: 400 mg 4 times daily; <2 yr: 200 mg 4 times daily. Renal impairment: CrCl (ml/min) 10-25: 800 mg tid. <10 800 mg every 12 hr. Intravenous Mucocutaneous herpes simplex in immunocompromised patients Adult: 5 mg/kg every 8 hr for 7 days. Dose to be given as IV infusion over 1 hr. Child: 10 mg/kg every 8 hr for 7 days. Herpes simplex encephalitis Adult: 10 mg/kg every 8 hr for 10 days. Child: >3 mth: 20 mg/kg every 8 hr for 10 days. Genital herpes Adult: 5 mg/kg every 8 hr for 5-7 days. Neonatal herpes simplex virus infections Child: Birth – 3 mth: 10 mg/kg every 8 hr for 10 days. Herpes zoster in immunocompromised patients Adult: >12 yr: 10 mg/kg every 8 hr for 7 days. Child: 20 mg/kg every 8 hr for 7 days. Renal impairment: Peritoneal dialysis: Half the usual dose once daily. Haemodialysis: Half the usual dose every 24 hr and an additional half-dose after haemodialysis. CrCl (ml/min) 25-50 Increase dose interval to 12 hr. 10-25 Increase dose interval to 24 hr.
Contraindication ::
Hypersensitivity.
Drug Precautions ::
Renal impairment. Pregnancy, lactation. Neurological abnormalities with significant hypoxia, serious hepatic or electrolyte abnormalities. Maintain adequate hydration.
Drug Side Effects ::
Nausea, vomiting, headache, diarrhoea, rash, haematological changes (occasional), increase in liver enzymes, burning, itching or erythema (topical use). Eye application may produce stinging, superficial punctate keratopathy, blepharitis or conjunctivitis. IV administration: Local reaction, pain, inflammation, phlebitis, extravasation leads to ulceration. Increase in BUN and/or creatinine. Rarely, renal failure. Potentially Fatal: Occasionally neurotoxicity after IV use: Lethargy, confusion, agitation, tremors, seizures, coma.
Pregnancy category ::
2
Drug Mode of Action ::
Activity against HSV types I and II and varicella-zoster virus is due to intracellular conversion of aciclovir to the monophosphate by viral thymidine kinase with subsequent conversion to the diphosphate and active triphosphate by cellular enzymes. This active form inhibits viral DNA synthesis and replication by interfering with viral DNA polymerase enzyme and being incorporated into viral DNA.
Drug Interactions ::
Probenecid, cimetidine and mycophenolate mofetil may increase the plasma concentration of aciclovir. Increased nephrotoxic effects w/ drugs that affect renal physiology (e.g. ciclosporin, tacrolimus).